- Home
- SHO vs IMCR Comparison
SHO vs IMCR Comparison
Compare SHO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHO
- IMCR
- Stock Information
- Founded
- SHO 1995
- IMCR 2008
- Country
- SHO United States
- IMCR United Kingdom
- Employees
- SHO N/A
- IMCR N/A
- Industry
- SHO Hotels/Resorts
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHO Consumer Discretionary
- IMCR Health Care
- Exchange
- SHO Nasdaq
- IMCR Nasdaq
- Market Cap
- SHO 1.8B
- IMCR 1.8B
- IPO Year
- SHO 1995
- IMCR 2021
- Fundamental
- Price
- SHO $9.75
- IMCR $33.42
- Analyst Decision
- SHO Hold
- IMCR Buy
- Analyst Count
- SHO 7
- IMCR 8
- Target Price
- SHO $9.21
- IMCR $57.00
- AVG Volume (30 Days)
- SHO 2.2M
- IMCR 288.3K
- Earning Date
- SHO 11-11-2025
- IMCR 11-05-2025
- Dividend Yield
- SHO 3.71%
- IMCR N/A
- EPS Growth
- SHO N/A
- IMCR N/A
- EPS
- SHO 0.02
- IMCR N/A
- Revenue
- SHO $934,999,000.00
- IMCR $356,145,000.00
- Revenue This Year
- SHO $6.47
- IMCR $29.67
- Revenue Next Year
- SHO $3.90
- IMCR $11.12
- P/E Ratio
- SHO $511.16
- IMCR N/A
- Revenue Growth
- SHO 0.37
- IMCR 26.78
- 52 Week Low
- SHO $7.45
- IMCR $23.15
- 52 Week High
- SHO $12.41
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- SHO 61.31
- IMCR 44.20
- Support Level
- SHO $9.50
- IMCR $35.33
- Resistance Level
- SHO $10.27
- IMCR $36.76
- Average True Range (ATR)
- SHO 0.23
- IMCR 1.46
- MACD
- SHO 0.02
- IMCR -0.12
- Stochastic Oscillator
- SHO 49.03
- IMCR 24.65
About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.